GlassScriptPhysician profile
Neveen Elkholy
NPI 1346245560
$947.13
in general payments reported to CMS, 2019-2025
15 companies · $44.77 in 2025
The $44.77 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41.13 · 2020: $179 · 2021: $235 · 2022: $198 · 2023: $109 · 2024: $141 · 2025: $44.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $294.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $201.03 | 2020-2022 | |
| Mannkind Corporation | $168.73 | 2020-2025 | Afrezza |
| Amgen INC. | $104.64 | 2020-2024 | Otezla, Repatha |
| Amarin Pharma, INC. | $69.21 | 2020-2021 | |
| Novo Nordisk INC | $64.11 | 2020-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $61.99 | 2019-2022 | |
| Exact Sciences Corporation | $59.62 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Cranial Technologies, INC | $40.86 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $39.85 | 2022-2024 | Airsupra |
| Lilly USA, LLC | $34.00 | 2023-2024 | Jardiance, Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $31.32 | 2022 | |
| Phadia US INC. | $29.33 | 2022-2024 | Immunocap |
| Vbi Vaccine (Delaware) INC. | $15.74 | 2023 | Prehevbrio |
| Pfizer INC. | $14.70 | 2024 | |
| Dermira, INC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neveen Elkholy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.